Monopar Therapeutics Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Monopar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $112.62. The average 1-year stock price forecast is 28.44% higher than the current stock price, while the lowest is $100 (+14.05%) and the highest is $130 (+48.27%).

Price Target: $112.62 (+28.44%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$100	$112.62	$109	$130
Change	+14.05%	+28.44%	+24.32%	+48.27%

Analyst Ratings

The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	10	10	10	9	9
Buy	4	4	4	4	4	4
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	14	14	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $101	Buy	Maintains	$101	+15.19%	Jun 2, 2026
Jeet Mukherjee BTIG	BTIG	Buy Maintains $104	Buy	Maintains	$104	+18.61%	Jun 2, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Reiterates $105	Buy	Reiterates	$105	+19.75%	Jun 1, 2026
Chad Messer Lake Street	Lake Street	Buy Maintains $103	Buy	Maintains	$103	+17.47%	Jun 1, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Buy Maintains $115	Buy	Maintains	$115	+31.16%	May 18, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

15.40M

EPS This Year

-2.90

from -1.85

EPS Next Year

-3.16

from -2.90

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-9.13M	-10.54M	-8.83M	-16.16M	-16.70M	-24.56M
Net Income	-9.10M	-10.52M	-8.40M	-15.59M	-13.72M	-20.16M
EPS	-	-	-	-	-1.85	-2.90
Free Cash Flow	-3.99M	-3.22M	-5.01M	-5.48M	-8.20M	-24.14M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.36
Avg	-2.90
Low	-5.45

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-